Doylestown, PA, United States of America

Donald E Kuhla

This inventor holds 59 USPTO granted patents, primarily in Cardiotonic Compounds (CPC class 5142). Top assignees: Rorer Pharmaceutical Corporation, William H. Rorer, Inc., Rhone-Poulenc Rorer Pharmaceuticals Inc.. Active years: 1984-1999.


% Patents Active = 100.0

Average Co-Inventor Count = 3.8

ph-index = 8

Forward Citations = 219(Granted Patents)

Forward Citations (Not Self Cited) = 203(Dec 10, 2025)


Inventors with similar research interests:


Company Filing History:


Years Active: 1984-1999

Loading Chart...
Areas of Expertise:
Cardiotonic
HMG-CoA Reductase
Heteroaromatic Compounds
Dibenzofurancarboxamides
Benzodiazinone
Pyridazinone
Pharmaceutical Compositions
Bicyclic Ethers
Thioethers
Pyridone
Aryl Substituted Heterocycles
Alkylene Amino
59 patents (USPTO):Explore Patents

Title: The Inventor Donald E Kuhla: Pioneering Innovations in Doylestown

Introduction: Donald E Kuhla is a distinguished inventor based in Doylestown, PA, known for his groundbreaking contributions to various fields through his innovative creations.

Latest Patents: Donald E Kuhla holds several patents in the areas of technology and engineering, showcasing his continuous commitment to pushing the boundaries of what is possible.

Career Highlights: With a career spanning several decades, Donald E Kuhla has established himself as a visionary inventor, with a keen eye for identifying gaps in the market and developing solutions that address them effectively.

Collaborations: Throughout his career, Donald E Kuhla has collaborated with leading industry experts, researchers, and engineers to bring his inventions to life, fostering a culture of innovation and excellence.

Conclusion: Donald E Kuhla's relentless pursuit of innovation and his passion for creating solutions that make a difference have solidified his reputation as a pioneering inventor in Doylestown and beyond.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…